香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 本公司謹此對該公告補充以下有關支付條款的資料。 支付條款 根據技術開發合同，江蘇康寧傑瑞同意於簽署合同後向蘇州康寧傑瑞支付人民幣 3,072,000元的首期付款，並啟動項目。餘下人民幣7,168,000元將以四筆里程碑付 款的形式支付，各款項與項目的具體交付成果及階段掛鈎。各里程碑付款的金額 及時間表乃由各方經公平磋商後釐定，確保符合相應交付成果及項目進度的工作 量、複雜程度及重要程度，包括完成工藝開發與確認、毒理批次的研製及放行檢 測及交付穩定性研究數據。 倘蘇州康寧傑瑞未能於截至2028年7月31日止三年內交付技術成果，江蘇康寧傑 瑞毋須支付額外款項。 1 除上文所披露者外，該公告所載的所有資料維持不變。本公告為該公告的補充， 應與該公告一併閱讀。 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） （股份代號：9966） 補充公告 關連交易－與蘇州康寧傑瑞的技術 ...

康宁杰瑞制药-B(09966)再涨超7%，截至发稿，涨6.56%，报9.59港元，成交额3218.92万港元。 消息面上，康宁杰瑞制药将于8月28日召开董事会会议以审批中期业绩。公司此前预计，上半年取得利 润不少于人民币2000万元，去年同期亏损约人民币4490万元。公司于报告期内转亏为盈，主要基于三项 授权合作的里程碑收入和商业化产品的销售收入。 此外，康宁杰瑞制药近日公告，公司自主研发的程序性死亡配体1(PD-L1)/整合素αvβ6双特异性抗体偶 联药物(ADC)JSKN022的新药临床试验申请已获中国国家药品监督管理局药品审评中心正式受理。公司 计划开展用于治疗晚期恶性实体瘤的JSKN022首次人体临床研究。目前全球范围内尚无靶向整合素αvβ6 或PD-L1的ADC上市，相关在研药物均处于临床研究阶段。 ...

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has seen a significant stock price increase, rising over 7% and currently trading at 9.59 HKD, with a trading volume of 32.19 million HKD. The company is set to hold a board meeting on August 28 to approve its mid-term performance, with expectations of a profit of no less than 20 million RMB for the first half of the year, compared to a loss of approximately 44.90 million RMB in the same period last year. The turnaround is attributed to milestone revenues from three authorized collaborations and sales from commercialized products. Additionally, the company has received acceptance for its clinical trial application for the dual-specific antibody-drug conjugate JSKN022, aimed at treating advanced malignant solid tumors, marking a significant development in the market as no similar targeted ADCs are currently available globally [1][1][1]. Financial Performance - The company anticipates a profit of at least 20 million RMB for the first half of the year, a notable recovery from a loss of around 44.90 million RMB in the previous year [1][1][1]. - The financial turnaround is primarily driven by milestone revenues from three authorized collaborations and sales from commercialized products [1][1][1]. Product Development - Corning Jereh Pharmaceutical has announced that its self-developed dual-specific antibody-drug conjugate JSKN022 has had its clinical trial application formally accepted by the National Medical Products Administration of China [1][1][1]. - The planned clinical study for JSKN022 will focus on treating advanced malignant solid tumors, with no existing targeted ADCs for integrin αvβ6 or PD-L1 currently available on the market [1][1][1].

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966.HK) expects to report a profit of no less than RMB 20 million for the six months ending June 30, 2025, compared to a loss of approximately RMB 44.9 million in the same period of 2024, indicating a turnaround from loss to profit driven by milestone revenues from three licensing collaborations and sales revenue from commercialized products [1] Financial Performance - The company anticipates a profit of at least RMB 20 million for the upcoming reporting period [1] - In contrast, the previous year’s corresponding period showed a loss of around RMB 44.9 million [1] Revenue Drivers - The turnaround to profitability is attributed to milestone income from three licensing agreements [1] - Additionally, revenue from the sales of commercialized products contributed to the positive financial outlook [1]

Core Viewpoint - 康宁杰瑞制药-B (09966)预计在截至2025年6月30日的六个月内实现利润不少于人民币2000万元，相较于2024年同期的亏损约人民币4490万元，显示出公司在财务上的显著改善 [1] Financial Performance - 康宁杰瑞制药-B在最新公告中提到，报告期内公司实现了转亏为盈，主要得益于三项授权合作的里程碑收入和商业化产品的销售收入 [1] Technology and Pipeline - 广发证券指出，康宁杰瑞制药-B在抗体药物偶联物（ADC）、双特异性抗体和多功能蛋白质工程方面拥有完善的专有技术平台，内部管线高度差异化，涵盖处于不同研发阶段的抗肿瘤药物 [1] - 公司差异化的生物大分子平台以及已展现初步临床疗效的ADC药物的发展潜力受到看好 [1]

Core Viewpoint - 康宁杰瑞制药-B expects to achieve a profit of no less than RMB 20 million for the six months ending June 30, 2025, compared to a loss of approximately RMB 44.9 million in the same period of 2024, indicating a turnaround from loss to profit driven by milestone revenues from three licensing collaborations and sales from commercialized products [1][1][1] Group 1 - Following the announcement, 康宁杰瑞制药-B's stock rose over 3%, currently trading at HKD 9.42 with a transaction volume of HKD 10.1093 million [1][1] - 广发证券 highlights the company's robust proprietary technology platform in ADC, bispecific antibodies, and multifunctional protein engineering, suggesting a strong differentiation in its internal pipeline [1][1] - The company’s pipeline includes various anti-tumor drugs at different stages of development, showcasing its potential for growth in the biopharmaceutical sector [1][1]

广发证券指出，公司在ADC、双特异性抗体和多功能蛋白质工程方面拥有完善的专有技术平台，内部 管线高度差异化，涵盖处于不同研发阶段抗肿瘤药物。该行看好公司差异化的生物大分子平台以及已展 现初步临床疗效的ADC药物的发展潜力。 消息面上，8月13日，康宁杰瑞制药-B发布公告，预期集团将于截至2025年6月30日止六个月取得利润不 少于人民币2000万元，而2024年同期则取得亏损约人民币4490万元。公告称，公司于报告期内转亏为 盈，主要基于三项授权合作的里程碑收入和商业化产品的销售收入。 智通财经APP获悉，康宁杰瑞制药-B(09966)盈喜后涨超3%，截至发稿，涨2.39%，报9.42港元，成交额 1010.93万港元。 ...

格隆汇8月13日丨康宁杰瑞制药-B(09966.HK)公布，集团预计截至2025年6月30日止六个月录得利润不少 于人民币20.0百万元，而2024年同期则录得亏损约人民币44.9百万元。公司于报告期内转亏为盈，主要 基于三项授权合作的里程碑收入和商业化产品的销售收入。 ...

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) expects to achieve a profit of no less than RMB 20 million for the six months ending June 30, 2025, compared to a loss of approximately RMB 44.9 million in the same period of 2024 [1] Group 1 - The company is transitioning from a loss to a profit during the reporting period [1] - The turnaround is primarily attributed to milestone revenues from three licensing collaborations and sales revenue from commercialized products [1]

公司于报告期内转亏为盈，主要基于三项授权合作的里程碑收入和商业化产品的销售收入。 智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，预期集团将于截至2025年6月30日止六个月取得利 润不少于人民币2000万元，而2024年同期则取得亏损约人民币4490万元。 ...